Boston Scientific (BSX) Expected to Announce Earnings on Wednesday

Boston Scientific (NYSE:BSX) is expected to be releasing its earnings data before the market opens on Wednesday, April 23rd. Analysts expect Boston Scientific to post earnings of $0.67 per share and revenue of $4.57 billion for the quarter. Boston Scientific has set its Q1 2025 guidance at 0.660-0.680 EPS and its FY 2025 guidance at 2.800-2.870 EPS.Investors interested in listening to the company’s conference call can do so using this link.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Trading Down 0.1 %

NYSE:BSX opened at $94.19 on Wednesday. Boston Scientific has a 52 week low of $66.80 and a 52 week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a market cap of $139.32 billion, a PE ratio of 75.35, a P/E/G ratio of 2.79 and a beta of 0.73. The business’s 50 day moving average is $100.11 and its two-hundred day moving average is $94.18.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company’s stock, valued at $560,103.60. The trade was a 75.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,183 shares of company stock valued at $13,948,476. 0.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC lifted its position in Boston Scientific Co. (NYSE:BSX) by 0.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,376 shares of the medical equipment provider’s stock after acquiring an additional 226 shares during the quarter. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 as of its most recent filing with the SEC. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. UBS Group lifted their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Morgan Stanley raised their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Friday, January 10th. Finally, Piper Sandler increased their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Two research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $109.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.